A Single-arm, Prospective Clinical Study of Camrelizumab Combined With Apatinib Mesylate in the Treatment of Relapsed Platinum-resistant Epithelial Ovarian Cancer
Latest Information Update: 05 Sep 2022
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 18 Sep 2020 Planned End Date changed from 30 Jun 2022 to 30 Aug 2022.
- 18 Sep 2020 Planned primary completion date changed from 30 Jun 2021 to 30 Aug 2021.
- 18 Sep 2020 Status changed from not yet recruiting to recruiting.